Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

Next Previous
Search
Trial Profile

An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BAY 794620 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bayer

Most Recent Events

  • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 08 Jan 2013 Planned End Date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
  • 11 Jan 2012 Planned end date changed from 1 Feb 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov (NCT01028755).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top